Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 9/20 | 0.38 |
| ▸ | HTR2A | P28223 | 9/20 | 0.38 |
| ▸ | HTR7 | P34969 | 9/20 | 0.38 |
| ▸ | HTR6 | P50406 | 9/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 4/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794984 | 0.95 | PIK3CD (0.45) | PIK3CDPIK3R1HTR1AHTR2AHTR7 | |
| SCHEMBL15485455 | 0.94 | PIK3CD (0.45) | PIK3CDPIK3R1HTR1AHTR2AHTR7 | |
| SCHEMBL798466 | 0.93 | PIK3CD (0.46) | PIK3CDPIK3R1HTR1AHTR2AHTR7 | |
| SCHEMBL10229577 | 0.92 | PIK3CD (0.45) | PIK3CDPIK3R1HTR1AHTR2AHTR7 | |
| SCHEMBL794500 | 0.92 | PIK3CD (0.48) | PIK3CDPIK3R1HTR1AHTR2AHTR7 | |
| SCHEMBL788856 | 0.91 | PIK3CD (0.45) | PIK3CDPIK3R1HTR1AHTR2AHTR7 | |
| SCHEMBL795082 | 0.91 | PIK3CD (0.45) | PIK3CDPIK3R1HTR1AHTR2AHTR7 | |
| SCHEMBL15485605 | 0.90 | PIK3CD (0.44) | PIK3CDPIK3R1HTR1AHTR2AHTR7 | |
| SCHEMBL15485770 | 0.89 | PIK3CD (0.46) | PIK3CDPIK3R1HTR1AHTR2AHTR7 | |
| SCHEMBL806240 | 0.89 | PIK3CD (0.46) | PIK3CDPIK3R1HTR1AHTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616469-B1 | 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE | EXELIXIS INC (US) | 2016-10-26 | — | — | EP | claimed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | claimed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | claimed |
| EP-2616469-B1 | 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE | EXELIXIS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2616469-B1 | 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE | EXELIXIS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012037226-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885PIK3R1 6/4885HTR1A 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.